We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Biotica Technology has reacquired worldwide rights from Pfizer for its rapamycin analogue program. The program focuses developing treatments for neuro-inflammatory and other diseases. PMLive
